Pfizer’s mRNA vaccine spurs coronavirus mutations that the vaccine-induced antibodies eventually cannot recognize

In the study, the Delta variant was pressured into four common mutations. The Pfizer and Moderna spike proteins that are transcribed in human cells do not prepare the body to fight the new variants that are being pressured into existence by these same vaccine programs. In fact, the Pfizer vaccine enhances the infectivity of the variant, causing the virus to be even more resistant to the human immune system. Scientists have identified three mutations of SARS-CoV-2 that are already outsmarting Pfizer’s mRNA vaccine technology. According to this study, after a fourth mutation emerges dominant in the population, the vaccinated will become more susceptible to severe illness.

“The receptor binding domain (RBD) of the spike protein binds to the host cell receptor ACE2, and the interaction mediates membrane fusion during SARS-CoV-2 infection,” the study authors wrote. “Neutralizing antibodies against SARS-CoV-2 are mainly directed to the RBD and block the interaction between the RBD and ACE2. Most SARS-CoV-2 variants have acquired mutations in the neutralizing antibody epitopes of the RBD, resulting in escape from neutralizing antibodies.”

The vaccine was only effective for a short amount of time against a single mutation. Most of the anti-receptor binding domain antibodies (induced by the vaccine) were able to recognize the spike protein and prevent severe infection. However, after four mutations, the antibodies induced by the vaccine were unable to recognize the spike protein. Consequentially, infectivity of Delta 4+ was enhanced, as the vaccinated became immune-compromised and more susceptible to severe illness.

Read More